Prolaris gene expression assay for assessing long-term risk of prostate cancer progression

References

Bishoff JT, Freedland SJ, Gerber L et al. (2014) Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. Journal of Urology 192: 409–14

Cancer Research UK (2014a) Prostate cancer key stats (online; accessed 2 February 2016)

Cancer Research UK (2014b) Prostate cancer risk factors (online; accessed 2 February 2016)

Cancer Research UK (2014c) Prostate cancer symptoms (online; accessed 2 February 2016)

Cancer Research UK (2014d) If prostate cancer comes back (online; accessed 17 February 2016)

Cooperberg MR, Simko JP, Cowan JE et al. (2013) Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. Journal of Clinical Oncology 31: 1428–34

Crawford ED, Scholz MC, Kar AJ et al. (2014) Cell cycle progression score and treatment decisions in prostate cancer: Results from an ongoing registry. Current Medical Research and Opinion 30: 1025–31

Crawford ED, Cole D, Lewine N et al. (2015) Evaluation of the economic impact of the CCP assay in localized prostate cancer. Journal of Clinical Oncology 33: Supplement 7, abstract 85

Cuzick J, Swanson GP, Fisher G et al. (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. The Lancet Oncology 12: 245–55

Cuzick JD, Berney M, Fisher G et al. (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. British Journal of Cancer 106: 1095–99

Cuzick J, Stone S, Fisher G et al. (2015) Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. British Journal of Cancer 113: 382–89

de Pouvourville G (2015) Cost-effectiveness analysis for the use of the CCP score in the management of early low risk prostate cancer in the French context. Value in Health 18: A358

Freedland SJ, Gerber L, Reid JE et al. (2013) Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. International Journal of Radiation Oncology Biology Physics 86: 848–53

Kranse R, Roobol M, Schroder FH (2008) A graphical device to represent the outcomes of a logistic regression analysis. The Prostate 68: 1674–80

Pepe MS, Feng Z, Janes H et al. (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. JNCI: Journal of the National Cancer Institute 100: 1432–8

Shore N, Concepcion R, Saltzstein D et al. (2014) Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Current Medical Research and Opinion 30: 547–553

Shore N, Kella N, Moran B et al. (2016) Impact of the cell cycle progression test on physician and patient treatment selection for localized prostate cancer. The Journal of Urology 195: 612–8

Thompson IM, Ankerst DP, Chi C et al. (2006) Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute 98: 529–34

Wilt TJ, Ahmed HU (2013) Prostate cancer screening and the management of clinically localized disease. British Medical Journal 346: f325